Novo Nordisk CEO says innovation in obesity may justify higher price in some segments
Reuters
Published Mar 08, 2024 06:09AM ET
Updated Mar 08, 2024 06:41AM ET
COPENHAGEN (Reuters) - Novo Nordisk (NYSE:NVO)'s CEO expects more people to take obesity drugs as prices fall over time, he told Reuters on Friday, adding that new generations of the medicine will justify higher prices in some segments.
"I expect that over time we'll see a lower price point that will cater for more and more patients getting on treatment," CEO Lars Fruergaard Jorgensen said in an interview.
Novo's shares rose to new record highs on Thursday after the company announced early trial data for an experimental obesity drug, amycretin.
"You will see new generations of innovations that will cater for even more differentiation, perhaps serve certain comorbidities better, and that can justify a higher price in some segments," Jorgensen said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.